Innovent Biologics
As of the edition of 20 October 2026, Innovent Biologics runs 64 drugs, 1 of them marketed; it is on route A at 12 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 34 |
| Went quiet | 2 |
| Stopped | 9 |
| Status not established | 18 |
| Total | 64 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Taletrectinib | Ends 2033 (patent) | 8 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 12 targets, route B at 0 targets.
All 12 rows on route A or B
In the product12 company-target rows on route A or B; 9 are not shown here, and no score is.
See all 12 targets where Innovent Biologics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 52 trials led
- Nutrition and metabolism: 22 trials led
- Immune system: 20 trials led